Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00747929
Recruitment Status : Completed
First Posted : September 8, 2008
Last Update Posted : May 10, 2018
Sponsor:
Information provided by (Responsible Party):
Shionogi Inc. ( Shionogi )

Tracking Information
First Submitted Date  ICMJE September 5, 2008
First Posted Date  ICMJE September 8, 2008
Last Update Posted Date May 10, 2018
Study Start Date  ICMJE June 2007
Actual Primary Completion Date November 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 25, 2018)
The change in body weight over the 54-week active therapy phase of the study [ Time Frame: 54 weeks ]
body weight at 54 weeks compared to body weight at start of treatment
Original Primary Outcome Measures  ICMJE
 (submitted: September 5, 2008)
The change in body weight (BW). [ Time Frame: 54 weeks ]
Change History Complete list of historical versions of study NCT00747929 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 25, 2018)
  • Change in body composition: calculated body mass index, waist circumference, hip circumference, and calculated waist-to-hip ratio [ Time Frame: 54 weeks ]
    Change in body weight, waist measurement, and hip measurement
  • Steady-state/trough pharmacokinetic analysis [ Time Frame: After 3, 12, 24, 36, and 54 weeks ]
    Trough plasma concentration at various times after start of treatment
  • Safety and tolerability of S-2367 [ Time Frame: 54 weeks ]
    number of adverse events or changes in laboratory values
Original Secondary Outcome Measures  ICMJE
 (submitted: September 5, 2008)
  • Change in body composition. [ Time Frame: 54 weeks ]
  • Dose-response for change in body weight. [ Time Frame: 54 weeks ]
  • Steady-state/trough PK analysis. [ Time Frame: 54 weeks ]
  • Safety & tolerability of S-2367(velneperit). [ Time Frame: 54 weeks ]
  • Assessment of psychological status and quality of life assessments. [ Time Frame: 54 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
Official Title  ICMJE A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800, or 1600 mg/Day of S-2367 Administered Orally Once Daily With a Reduced Calorie Diet in Obese Males and Females
Brief Summary
  1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects
  2. To evaluate the safety and tolerability of S-2367 during 54 weeks of drug exposure
  3. To evaluate the steady-state/trough pharmacokinetics of S-2367
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Obesity
Intervention  ICMJE
  • Drug: S-2367 Placebo
    four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,
  • Drug: S-2367 800 mg
    two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks
    Other Name: Velneperit
  • Drug: S-2367 1600 mg
    four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
    Other Name: Velneperit
  • Other: Reduced Calorie Diet
    A diet with restricted calorie content
Study Arms  ICMJE
  • Placebo Comparator: S-2367 Placebo
    Placebo + reduced calorie diet
    Interventions:
    • Drug: S-2367 Placebo
    • Other: Reduced Calorie Diet
  • Experimental: S-2367 800 mg
    S-2367 800 mg q.d. + reduced calorie diet
    Interventions:
    • Drug: S-2367 800 mg
    • Other: Reduced Calorie Diet
  • Experimental: S-2367 1600 mg
    S-2367 1600 mg q.d. + reduced calorie diet
    Interventions:
    • Drug: S-2367 1600 mg
    • Other: Reduced Calorie Diet
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 19, 2011)
724
Original Actual Enrollment  ICMJE
 (submitted: September 5, 2008)
900
Actual Study Completion Date  ICMJE January 2009
Actual Primary Completion Date November 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Males and females between 18 and 65 years of age and body mass index between 30.0 to 45.0 kg/m2, inclusive, and a weight that has not fluctuated by more than 3% for the last 3 months
  • Medically stable for 3 months prior to Visit 1 and in otherwise good health, with no clinically significant findings from medical history, physical examination, 12-lead electrocardiograms (ECG), and vital signs
  • Clinical laboratory evaluations (including clinical chemistry [fasted at least 8 hours], complete blood count, urinalysis, including creatine phosphokinase, amylase, lipase, lipid profile, insulin, Homeostatic Model Assessment of Insulin Sensitivity Index, hemoglobin A1c, thyroid stimulating hormone, free thyroxine, cortisol, iron, and ferritin) within the reference range for the test laboratory, unless deemed not clinically significant by the investigator
  • Males will be sterile or agree to use an approved method of contraception. Some of the approved methods of contraception for males includes a surgically sterile (for at least 3 months prior to Visit 1) female sexual partner; a postmenopausal (for at least 1 year since last menstrual cycle) female sexual partner; a female sexual partner who uses (for at least previous 3 months prior to Visit 1 and during study) oral, implantable, transdermal, or injectable oral contraceptives; or use of the following double-barrier method: male condom with spermicide
  • Females will be non-pregnant, non-lactating, and either postmenopausal for at least 1 year since last menstrual period, surgically sterile for at least 3 months prior to Visit 1, or agree to use an approved method of contraception. Some of the approved methods of contraception for females include a sterile (for at least 3 months prior to Visit 1) male sexual partner; use of oral, implantable, transdermal, or injectable oral contraceptives; or use of one of the following double-barrier methods: intrauterine device with spermicide, diaphragm with spermicide, cervical cap with spermicide, female condom with spermicide, or a male condom with spermicide by the male sexual partner
  • Able to understand and willing to sign an informed consent form and comply with all study procedures

Exclusion Criteria:

  • History or clinical manifestations of significant metabolic, hepatic, immunological (e.g., human immunodeficiency virus/ acquired immunodeficiency syndrome), renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), urological, neurological, or psychiatric disorders
  • History or presence of an abnormal ECG, which in the investigator's opinion, is clinically significant
  • History or evidence of a psychological disorder, other than stable or controlled anxiety or depression, including but not limited to the schizophrenias. Treatment with an antidepressant or anxiolytic drug(s) will be permitted if the dose and form has remained stable for at least the previous 3 months and the medication is not precluded/ excluded by this protocol because of potential effects on body weight and is not expected to change during the remainder of this clinical protocol
  • History or evidence of an eating disorder with a compensatory behavior such as "purging bulimia nervosa" or "non-purging bulimia nervosa"
  • History of obesity of endocrine origin
  • History of type 1 or type 2 diabetes mellitus
  • Clinically significant hypertension defined as blood pressure > 160/90 mm Hg for either the systolic or diastolic values in either the untreated or treated state
  • Clinically significant GI history or surgery. NOTE: Appendectomy and cholecystectomy will be allowed
  • Gastric bypass surgery, stomach banding surgery, or any other surgical procedure(s) that attempt to promote/aid weight loss
  • History of polycystic ovarian syndrome
  • History of fenfluramine or dexfenfluramine or "fen-phen" administration with abnormal findings on echocardiograms at the time of "fen-phen" discontinuation
  • History of participation in any weight loss program within 3 months prior to Visit 1
  • History of body weight loss or gain greater than 3% within 3 months prior to Visit 1
  • History of alcoholism or drug addiction/ substance abuse within 1 year prior to Visit 1
  • History of any tobacco-containing or nicotine-containing product use (including cigarette, pipe, cigar, chewing, nicotine patch, or nicotine gum) within 1 year prior to Visit 1
  • Participation in any other investigational study drug trial in which receipt of investigational study drug occurred within 3 months prior to Visit 1
  • Previous use or participation in a study of S-2367 or any other neuropeptide Y5 agonist or antagonist
  • Participation in any weight loss medication/product study in which receipt of weight loss medication/product occurred within 3 months prior to Visit 1
  • Use of any prescription or non-prescription over-the-counter (OTC) medication/product or herbal/phytotherapeutic/plant-derived medications/products within 3 months prior to Visit 1 that is intended to induce weight loss, appetite suppression, weight control, or treat obesity, including, but not limited to, phentermine, sibutramine, orlistat, ephedra, rimonabant and other anorexogenics and/or stimulants, as well as topiramate
  • Use of chronic medications/products within 3 months prior to Visit 1 or during the study that are known to cause weight gain. The list includes but is not limited to amitriptyline (Elavil), paroxetine (Paxil), setraline (Zoloft), and mirtazepine (Remeron)
  • Use of any prescription or non-prescription OTC medications/products within 1 month prior to Visit 1, unless deemed acceptable by the investigator. Some examples of allowed medications are stable use (over the 3-month period prior to Visit 1) of the following will be allowed: hormone replacement therapy (e.g., for postmenopausal women); antihypertensive agents (e.g., for hypertensive subjects); statins (e.g., for hyperlilidaemia); thyroid replacement therapy (e.g., for thyroid subjects and provided thyroid replacement therapy has been stable for 3 months and no clinically significant changes in thyroid stimulating hormone and/or free thyroxine occur[s] during the study); oral, implantable, transdermal, or injectable contraceptive(s), etc. Anticholinergics (if used acutely), centrally acting antihistamines, and anti-inflammatories will be also allowed. Continued, stable, moderate use (over 3 month period prior to Visit 1) of vitamins and minerals is allowed and additional use of multivitamin-mineral supplements (non-herbal) may be allowed by the investigator (or designee) as part of the study diet program
  • Donation of blood or blood products 3 months prior to Visit 1 or during the entire study
  • Any acute or chronic condition that, in the opinion of the investigator, would limit the subject's ability to complete and/ or participate in this clinical study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00747929
Other Study ID Numbers  ICMJE 0701A2823
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Shionogi Inc. ( Shionogi )
Study Sponsor  ICMJE Shionogi
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Shionogi Clinical Trials Administrator Clinical Support Help Line Shionogi
PRS Account Shionogi Inc.
Verification Date May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP